BRAF and cholangiocarcinoma: CCA is not usually a hypervascular tumor, but regorafenib is still considered a potential therapeutic agent for this disease since several molecular alterations, including the disruption of the MAPK pathway and the activation of Ras and BRAF mutations, have been described in CCA [25–27].